Global Account Director || Life Science Intelligence Leader || Drug Development & IP Solutions
Did you miss it? Last month, we introduced our groundbreaking chemical modification search tool! If you are working in oligonucleotide therapeutics, and want to enhance your innovation capabilities, take a look at the link below and explore what this revolutionary tool can do for you! #oligonucleotide #RNA #chemicalmodification #innovation
?? Live from the 19th BioPharma Drug Discovery Nexus Conference! Join Lars Nieba CEO at Engimmune Therapeutics, as he unveils groundbreaking insights on coupling protein engineering with AI to develop multi-specific, soluble TCR-based cell engagers for oncology and auto-immune diseases. Don't miss this enlightening session! #BioPharma #DrugDiscovery #Innovation #NexusConference #Switzerland #Proteinengineering #AI #Cell #TCR #ImmuneDiseases #ProcurementDirect #LiveUpdate #ConferenceLive #DiscoveryConference #EuropeEvent
LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Roche buys out CAR-T partner Poseida for $1B upfront: Roche is acquiring its cell therapy and genomic medicines partner Poseida Therapeutics, the companies said Tuesday morning. The Basel-based pharma giant will pay $9 per share in upfront cash, giving Poseida ... #lucidquest #genetherapy #celltherapy
Ready to take your mRNA therapeutics to large-scale manufacturing? See how you can get the process started in our recent blog “Scaling up: moving from research to large-scale RNA production for mRNA therapeutics.” Explore critical factors to keep in mind, so your process is smooth and successful: https://ow.ly/1QKF50Tvti6 Read it for yourself!
Review (2021): Overcoming the challenges of tissue delivery for #oligonucleotide therapeutics #antisense oligonucleotides (#ASOs) #siRNA https://lnkd.in/eQbfRdne
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Gene&Cell Therapy >> Roche buys out CAR-T partner Poseida for $1B upfront: Roche is acquiring its cell therapy and genomic medicines partner Poseida Therapeutics, the companies said Tuesday morning. The Basel-based pharma giant will pay $9 per share in upfront cash, giving Poseida ... #lucidquest #genetherapy #celltherapy
If you are working on a biologic therapy for a #neurodegenerative disease or #stroke, consider registering for the upcoming #Blueprint #Neurotherapeutics for biologics (BPN-Biologics) Q&A webinar on Oct. 23 at 2pm ET. This would include biotechnology products and biologics-based therapies such as peptides, proteins, and antibodies, gene-based therapies such as oligonucleotide and viral based cell therapies, as well as other novel emerging therapies including microbial and microbiome therapies. #BPNBiologics?provides #nondilutive funding and resources for drug discovery and development, from lead optimization through phase I clinical testing. Investigators interested in learning about the program can register here: https://lnkd.in/ezN-_r-U
??? [POSTER] Promega's automated workflow for exosomal RNA isolation enables rapid, high-throughput miRNA extraction for RNA-seq and RT-qPCR, reducing processing time to under 2 minutes. ?? Download the full poster to explore its potential for advancing exosome-based therapeutics: https://bit.ly/4efQYc7
The authors of this research identify a library of 3-amino-1,2,4-triazine derivatives that inhibit PDK activity and use Enzo’s MITO-ID? Membrane Potential Detection Kit in human pancreatic PSN-1 cells, to further characterize the mechanisms by which they work. They aim to further test these derivative compounds for efficacy as therapeutics against KRAS-mutant pancreatic ductal adenocarcinoma. Read the paper > https://lnkd.in/e8AnhiHN Learn more about Enzo’s product > https://lnkd.in/eTnJyf66 #ScientistsEnablingScientists #drugdiscovery #livecell #cellularassay
Genenta Science has?expanded?its partnership with AGC Biologics, amending their Development and Master Services Agreement to secure an exclusive GMP suite at AGC Biologics’ Cell and Gene Center of Excellence in Milan, Italy. Genenta Science (Nasdaq: GNTA) #GenentaScience #AGCBiologics #partnership #agreement #GMPsuite #pharmanews #pharmamanufacturing https://lnkd.in/gUVX3-v8
It's been a strong start to 2025 for Outrun Therapeutics, with CEO Carolyn Porter visiting San Francisco for the 43rd Annual J.P. Morgan Healthcare Conference, and Matthew Fyfe joining us as our Chief Scientific Officer. ? At Outrun, we are the E3 ligase inhibitor and protein stabilisation specialist, utilising our proprietary X-E?L discovery platform to identify first-in-class small molecule drugs targeting E3 ligases. ? But what is an #E3ligase? Watch the below video to find out, and visit our website to discover more about the relevance of E3 ligase inhibition as a therapeutic approach, and how we are leading the way. ? #drugdiscovery #biotech #oncology
